Therapeutic Drug Monitoring with Cyclosporine

Introduction to Cyclosporine Monitoring

Cyclosporine C2 levels are used for more accurate therapeutic drug monitoring as they better reflect overall drug exposure and correlate better with clinical outcomes than traditional trough (C0) levels, allowing for optimized dosing that balances efficacy and toxicity 1, 2
The American Thoracic Society and other guideline societies provide recommendations on cyclosporine monitoring, emphasizing the need for careful management 1
Cyclosporine is a "critical-dose drug" with a narrow therapeutic index, where small changes in dose or plasma concentration can result in clinically significant changes in efficacy and/or toxicity, emphasizing the need for careful monitoring in kidney transplant recipients 2

In kidney transplantation, target C2 levels are between 600-1500 ng/mL 1
In lung transplantation, target C2 levels are 600-1500 ng/mL 1
In patients with idiopathic nephrotic syndrome, C2 levels ≥800 μg/L are associated with maximal pharmacological effect, although optimal targets are still being researched 2

C2 appears to be a better predictor of area under the curve (AUC) than C0 in children with idiopathic nephrotic syndrome 2
C2 levels are used to monitor treatment in focal segmental glomerulosclerosis and other glomerular diseases 2
C2 monitoring may improve renal function in patients receiving cyclosporine, particularly in lung transplantation 1

Reduce dose if serum creatinine increases by 30% above baseline, even if within normal range, to mitigate nephrotoxicity risk 2, 3
Medications affecting CYP3A4 system, such as calcium channel blockers like amlodipine, will alter cyclosporine levels 1
More frequent monitoring of cyclosporine levels is indicated in patients with fluctuating renal function, recent infection or illness, medication changes that could affect cyclosporine metabolism, or abnormal laboratory values 2

Different cyclosporine formulations (e.g. Neoral vs. generic) have different pharmacokinetics and are not bioequivalent, cannot be used interchangeably without physician supervision 2
Blood must be drawn exactly 2 hours post-dose for accurate C2 level results
The KDIGO guidelines recommend ongoing monitoring of calcineurin inhibitors like cyclosporine in kidney transplant recipients to maintain appropriate immunosuppression levels and prevent rejection while minimizing toxicity 4

Baseline risk factors for kidney transplant recipients on cyclosporine include long-term transplant recipient status, recent infections with documented acute kidney injury (AKI), elevated creatinine levels, reduced glomerular filtration rate (GFR), and multiple medications with potential interactions 2
Trough levels may not always correlate well with overall drug exposure, whereas the C2 monitoring approach provides a better correlation with clinical outcomes 2